A pilot study assessing the clinical effectiveness of dipyridamole in patients with active disease on methotrexate for rheumatoid arthritis with imaging analysis

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN28468355

Enrollment

Registered

2005-09-30

Start date

2004-01-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis Musculoskeletal Diseases Other rheumatoid arthritis

Interventions

Randomised controlled trial

Eligibility

Inclusion criteria

Inclusion criteria: Patients attending general Rheumatology clinics will be invited to participate

Exclusion criteria

Exclusion criteria: 1. Pregnant or nursing women 2. Concomitant serious medical conditions presently severe, progressive or uncontrolled 3. Contraindication to proposed therapeutic agents 4. Taking theophylline and/or treated for asthma

Design outcomes

Primary

Measure	Time frame
Clinical efficacy of dipyridamole combined with MTX at 8 weeks, as measured by DAS28 score with EULAR response	—

Secondary

Measure	Time frame
1. Number of patients requiring additional anti-rheumatic therapy 2. Change in the following individual clinical, laboratory and quality of life outcome measurements: 2.1. C-reactive protein (CRP) 2.2. Health Assessment Questionnaire (HAQ) 2.3. Visual Analogue Scale (VAS) 2.4. Early morning stiffness/tender and swollen joint count (66/68) ratio	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026